Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK delivers sales, earnings and cash flow growth in 2018
Total EPS 73.7p, +>100% AER, +>100% CER; Adjusted EPS 119.4p +7% AER, +12% CER
-
GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture
GSK has reached agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture.
-
GSK Science in the Summer™ unveils 2019 curriculum
Free STEM program in partnership with The Franklin Institute to reach 26,000 students nationwide this year.
-
GSK receives a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza
GSK receives a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza
-
ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection
ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies
-
GSK sponsors GSK Science in the Summer™ with Morehead Planetarium
Morehead Planetarium & Science Center is partnering with GSK for the 11th year to present GSK Science in the Summer™
-
Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
TESARO announced the presentation of data from the Phase 1/2 GARNET study evaluating dostarlimab
-
Middle school teachers get hands-on experience in STEM careers
Second annual emPowering STEM Classroom to Career Conference to take place in RTP March 25th
-
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refracatory multiple myeloma
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate
-
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca
-
Eighty Philadelphia teachers to attend “Empowering STEM” on Monday, April 8th
Empowering STEM is full-day conference supporting teachers in tackling Philadelphia’s STEM career challenge.
-
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine)
-
GSK invests $100 million to expand long-term vaccine manufacturing capabilities in Hamilton, MT
New investment in its manufacturing site in Hamilton, MT to expand the production capacity of key components of the adjuvant system
-
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection
ViiV Healthcare announces CHMP Positive Opinion for Dovato®
-
GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above
FDA approval marks the first medicine in the US approved for children with systemic lupus erythematosus (SLE)
-
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
-
GSK delivers sales of £7.7 billion +6% AER, +5% CER
Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER
-
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
-
GSK Science in the Summer™ Aims to Inspire Youth with STEM Learning through the ‘Science of Me’
Science in the Summer kicks off registration on May 13 and promises a one-of-a-kind science experience.
-
GSK’s strong science prominent at ATS 2019
GSK will present more than 70 abstracts at the American Thoracic Society (ATS) International Conference 17-22 May, Dallas, US
